Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | PNMT | P11086 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29442874 | 1.00 | ALDH1A1 (0.59) | ALDH1A1POLBHTTIDO1CYP3A4 | |
| SCHEMBL29442805 | 0.84 | ALDH1A1 (0.54) | ALDH1A1POLBHTTCYP3A4SLC5A2 | |
| SCHEMBL21384002 | 0.84 | ALDH1A1 (0.54) | ALDH1A1POLBHTTCYP3A4SLC5A2 | |
| SCHEMBL21384161 | 0.76 | ALDH1A1 (0.68) | ALDH1A1IDO1CYP3A4PNMTTAAR1 | |
| SCHEMBL29442868 | 0.76 | ALDH1A1 (0.68) | ALDH1A1IDO1CYP3A4PNMTTAAR1 | |
| SCHEMBL14559847 | 0.75 | ALDH1A1 (0.44) | ALDH1A1SLC6A2SLC6A4SLC5A2 | |
| SCHEMBL14559844 | 0.75 | ALDH1A1 (0.44) | ALDH1A1SLC5A2 | |
| SCHEMBL3298586 | 0.75 | IDO1 (0.64) | ALDH1A1POLBHTTIDO1CYP3A4 | |
| SCHEMBL21384092 | 0.74 | ALDH1A1 (0.64) | ALDH1A1IDO1TAAR1 | |
| SCHEMBL29442786 | 0.74 | ALDH1A1 (0.64) | ALDH1A1IDO1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12180221-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-31 | — | — | US | disclosed |
| CN-118084800-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084801-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-112312913-B | Compounds and uses thereof | 詹森药业有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20230078764-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-16 | — | — | US | disclosed |
| US-20220298168-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-22 | — | — | US | disclosed |
| CN-114174273-A | Compounds and uses thereof | 优曼尼蒂治疗公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3941908-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-112312913-A | Compounds and uses thereof | 优曼尼蒂治疗公司 | 2021-02-02 | — | — | CN | disclosed |
| EP-3768269-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| WO-2020198026-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020198026-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2019183587-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019183587-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230078764-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | ALDH1A1 293/4885POLB 3273/4885HTT 216/4885 |
| US-20220298168-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | ALDH1A1 656/4885POLB 3788/4885HTT 6/4885 |
| US-12180221-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | ALDH1A1 656/4885POLB 3788/4885HTT 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.